Skip to content
TrialScanner

NCT02956122

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Phase 2/Phase 3TerminatedTAKLeadKMDACollaborator

Registry record

Lead sponsor
Baxalta now part of Shire
Conditions
Graft Versus Host Disease
Primary completion
May 3, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02956122 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02956122: A Phase 2/3 Study of GLASSIA... | TrialScanner